Valiant Laboratories growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025
+78.0%−26.7%
+236.6%+44.3%
+105.2%+34.7%
−48.5%−788.7%
0.0%−492.3%
+15.7%+17.0%
+32.7%−1.1%
−894.4%−30.3%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

VALIANTLAB₹128.33

Valiant Laboratories Limited

· Pharma & Health
₹ CrorePeersALBERTDAVDHALEOSLABSZIMLABMEDICOMEDICAMEQANUHPHRAHCLWANBURYMcap ₹697 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—-26.7+78.0—
EBITDA Growth—+44.3+236.6—
EBIT Growth—+34.7+105.2—
Net Income Growth—-788.7-48.5—
EPS Growth—-492.30.0—
Total Assets Growth—+17.0+15.7—
Total Equity Growth—-1.1+32.7—
Cash from Operations Growth—-30.3-894.4—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.